Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07455851) titled 'A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma' on March 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Regeneron Pharmaceuticals
Condition:
Relapsed Refractory Multiple Myeloma (RRMM)
Intervention:
Drug: Linvoseltamab
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: March 23, 2026
Target Sample Size: 150
To know more, visit https://cl...